Thompson Davis & Co’s Genmab GMAB Stock Holding History

Thompson Davis & Co’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,750	Closed	-$202K	–	123
2024 Q1	$202K	Buy	+6,750	New	+$198K	0.14%	96

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's GMAB Position: Q2 2024 in Review

Thompson Davis & Co sold out of Genmab (GMAB) in Q2 2024, closing a stake of 6,750 shares — an estimated $202K sold.

Thompson Davis & Co first reported a position in GMAB in Q1 2024 and held it in 1 quarter. The position peaked at $202K in Q1 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

Thompson Davis & Co reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
Thompson Davis & Co sold 6,750 Genmab shares in Q2 2024, an estimated $202K.
Thompson Davis & Co first reported a position in Genmab in Q1 2024 and held it in 1 quarter.
Thompson Davis & Co's Genmab position peaked at $202K in Q1 2024.
219 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on Thompson Davis & Co's 13F filing for Q2 2024, filed 23 Jul 2024.